NCT04991480 - A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

390

Participants

Timeline

Start Date

September 13, 2021

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Advanced CancerMetastatic CancerBreast Cancer

Interventions

DRUG

ART4215

Participants will receive ART4215 by mouth daily in 21-day cycles.

DRUG

Talazoparib

Talazoparib will be administered at a dose of 1 mg or 0.75 mg by mouth daily in 21-day cycles.

DRUG

Niraparib

Niraparib will be administered at a dose of 200 mg or 300 mg by mouth daily in 21-day cycles.

Trial Locations (8)

Memorial Sloan Kettering Cancer Center, New York

University of Pennsylvania/Abramson Cancer Center, Philadelphia

Florida Cancer Specialists, Orlando

Tennessee Oncology, Nashville

Oklahoma University, Oklahoma City

MD Anderson Cancer Center, Houston

Yale School of Medicine, New Haven

Sarah Cannon Research Institute, London